Evidence map›Paper›PMID 42152003›Full record

ArticleJournal of translational medicine2026

METTL3-driven m

Fan Zhang, Linwei Wang, Qizhen Chen, Shuai Zhu, Xuejun Gong, Yebin Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fan Zhang *Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
Linwei Wang *Hepatobiliary and Pancreatic Surgery, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Qizhen ChenPancreatic Surgery, Xiangya Hospital, Central South University, No.87 Xiangya Road, Kaifu District, Changsha, Hunan, 410008, China.
Shuai ZhuPancreatic Surgery, Xiangya Hospital, Central South University, No.87 Xiangya Road, Kaifu District, Changsha, Hunan, 410008, China.
Xuejun GongPancreatic Surgery, Xiangya Hospital, Central South University, No.87 Xiangya Road, Kaifu District, Changsha, Hunan, 410008, China.
Yebin LuPancreatic Surgery, Xiangya Hospital, Central South University, No.87 Xiangya Road, Kaifu District, Changsha, Hunan, 410008, China. luyebin6@csu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic cancer is characterized by asymptomatic early stages, fast progression, and dismal survival rates. Therefore, a better understanding of immune evasion is required to create more effective treatments. m

resultsGEO microarray datasets identified pancreatic cancer differentially expressed genes (DEGs) and m

conclusionsIn conclusion, targeting METTL3 or ADAM10, or intervention in the m

Indexed as

ADAM10 ProteinAdenosineAmyloid Precursor Protein SecretasesDisease ProgressionHistocompatibility Antigens Class IImmune EvasionMembrane ProteinsMethyltransferasesPancreatic NeoplasmsAnimalsApoptosisCell Line, TumorCell MovementEpitranscriptomeGene Expression Regulation, NeoplasticHumansADAM10 ProteinADAM10 protein, humanAdenosineAmyloid Precursor Protein SecretasesHistocompatibility Antigens Class IHypoxia-Inducible Factor 1, alpha SubunitMembrane ProteinsMethyltransferasesMETTL3 protein, humanMHC class I-related chain AN-methyladenosineADAM10HypoxiaImmune escapem6A modificationMETTL3Pancreatic cancer

Identifiers

PMID42152003
PMCPMC13386607

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.